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Abstract We demonstrate that small heat shock proteins 
(sHsp) inhibit in vitro amyloid formation by the Alzheimer's 
Aßi 42 polypeptide as detected by a thioflavine T fluorescence 
assay and electron microscopy. Human sHsp27 (0.50-3.0 (JM) 
inhibited amyloid formation from 20 uM Aßx 42 by 23-75% in 
24 h. In contrast, treatment of pre-formed amyloid with 0.5-3.0 
(jM sHsp27 only reduced the fluorescence signal by 6-36%. The 
data suggest that ordered fibril formation may represent a form 
of off-pathway aggregation that can be prevented by chaperone 
action. The data raise the possibility that age-related changes in 
chaperone function could contribute toward the pathogenesis of 
Alzheimer's and other amyloid-associated diseases. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Alzheimer's disease (AD) is a neurodegenerative disease 
characterized by intravascular or extravascular fibrillar pro-
tein deposits in intracellular tangles and extracellular plaques 
[1]. Extracellular plaques may be either diffuse with limited 
degeneration of surrounding neurites or neuritic with exten-
sive damage to surrounding neurites and increased numbers of 
associated microglia and oligodendrocytes [1]. Both plaque 
types are comprised of a mixture of 39^43 amino acid poly-
peptides, designated Aßs [2,3], that originate by the processing 
of several integral plasma membrane proteins (677-770 amino 
acids) derived from the amyloid precursor protein (APP) by 
alternative splicing of a single gene on chromosome 21 [4-6]. 
Aßs spontaneously form amyloid in vitro [7] and are cytotoxic 
in cell culture [8-10] and in vivo when injected into rat and 
monkey brain [11,12]. In aged primate cortex, Aßi_4o pro-
duced lesions whose size was dose dependent and which 
closely resembled those in AD [12]. 
The mechanisms by which amyloid kills cells are unknown, 
although recent evidence implicates microglial cell-mediated 
oxidative stress mediated by extracellular amyloid interaction 
with the receptor for advanced glycation end products 
(RAGE) [13]. Cell death is commonly associated with all amy-
loidoses. For example, amyloid formation by the human islet 
amyloid precursor protein (IAPP) is associated with loss of 
pancreatic ß cells in non-insulin dependent diabetes mellitus 
(NIDDM). We demonstrated that expression of IAPP in 
""Corresponding author. 4-407 ALFRED, Mayo Clinic, Rochester, 
MN 55906, USA. Fax: (1) (507) 255-4828. 
E-mail: eberhardt@mayo.edu 
COS-1 cells led to the formation of intracellular amyloid 
and cell death [14]. COS-1 cells were killed by intracellular 
amyloid concentrations that were far lower than those re-
quired to kill cells by adding IAPP to cultured cells [15], 
suggesting that intracellular amyloid deposition may represent 
a primary event in the pathogenesis of many amyloidoses, 
including NIDDM and AD [14]. A corollary of this hypoth-
esis is that cells have evolved protective mechanisms to either 
prevent amyloidogenesis or counteract the cytotoxic actions of 
intracellular amyloid [14] with disease onset being due to an 
alteration or breakdown in the cell's protective mechanisms. 
To begin to test this hypothesis, we investigated an in vitro 
model of amyloidogenesis by which a number of candidate 
anti-amyloidogenic mechanisms could be readily evaluated. 
We examined in vitro amyloidogenesis by Aßi_42, since this 
system has been extensively characterized [16,17]. As an initial 
candidate protective mechanism, we chose to study the effects 
of heat shock proteins (Hsp)/chaperones on amyloidogenesis. 
These proteins form a large, diverse family of essential pro-
teins that are distributed in virtually all subcellular compart-
ments and whose primary function is to mediate trafficking, 
folding and assembly of monomeric and oligomeric polypep-
tides into their physiologic structures [18]. Although the exact 
mechanisms by which heat shock proteins help to fold pro-
teins is unknown, one of their principal actions is to prevent 
off-pathway aggregation, a non-productive event which pre-
vents proteins from acquiring their functional conformation. 
Therefore, we sought to determine if amyloidogenesis repre-
sented a form of off-pathway aggregation, that could be inter-
vened through some Hsp/chaperone function. 
2. Materials and methods 
2.1. Peptide synthesis 
Aßi-42 was synthesized (ABI 431A synthesizer, Perkin Elmer/Ap-
plied Biosystems) using triple couplings for the R5 and Hf¡ residues to 
prevent generation of peptides lacking one or both of these residues. 
The sequence of the peptide was verified by direct sequencing. Amino 
acid analysis revealed that the crude peptide was 72% pure by weight 
and after purification by reverse phase HPLC on a Vydac C8 column 
(Separations Group), the peptide content was reduced to 54% by 
weight. The crude and purified peptides contained 8.9 and 2.4% tri-
fluoroacetate (Galbraith Laboratories) by weight, respectively. Since 
sequence analysis of the crude peptide indicated that the material was 
not significantly contaminated with deletion peptides, the difference in 
peptide composition is most likely due to differing water content. The 
behavior of the crude and purified peptides in amyloidogenesis assays 
was comparable, although the HPLC purified peptide formed amyloid 
at somewhat slower rates. Therefore, the crude material was used for 
all of the studies reported below. 
2.2. In vitro amyloidogenesis 
Reactions were performed in 10 mM Tris-HCl (pH 7.4), 100 mM 
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NaCl, 5% dimethylsulfoxide (DMSO) in a final volume of 300 ul with 
constant stirring at 22°C. Aßi_42 in DMSO (100-400 uM) was added 
to the reaction mixture at a 1:20 dilution to achieve the final concen-
trations of 5-20 |J.M. Human sHsp27, murine sHsp25 and a-crystallin, 
containing both A and B forms, were from StressGen Biotechnolo-
gies, Inc. Lactate dehydrogenase (LDH) and bovine serum albumin 
(BSA) were from Sigma Chemical Co. 
2.3. Thioflavine T (ThT) fluorescence assay 
Fluorescence was measured on a SLM 8000 spectrofluorometer 
(Spectronic Instruments, Inc.) at 22°C with excitation and emission 
wavelengths of 450 and 482 nm, respectively. Fluorescence assays 
were performed in 50 mM glycine (pH 9.0), 1 uM ThT in a final 
volume of 1.5 ml according to Naiki et al. [19-21]. 
2.4. Electron microscopy 
Samples were spread on carbon-coated Formvar grids, stained with 
1% phosphotungstic acid for 15 min, and washed with distilled water 
over dental wax. Specimens were examined with a Jeol 1200 electron 
microscope with an acceleration voltage of 60 kV. 
2.5. Data analysis 
All experiments were replicated at least three times. Initial rates 
(arbitrary fluorescence units h_1) were calculated from linear regres-
sion slopes of the raw data. Initial rates were analyzed by multivariate 
ANOVA with post hoc Bonferroni Wests. 
3. Results 
Amyloid is a highly ordered fibril of varying length with a 
diameter of ca. 8-12 nm that is rich in ß-pleated sheet struc-
ture [22]. To examine the influence of heat shock proteins/ 
chaperones on amyloid formation, an assay specific for this 
ordered structure was required. Although many studies of in 
vitro amyloid formation have utilized light scattering meas-
urements, non-ordered (amorphous) aggregation may contrib-
ute to the signal. Since heat shock proteins can prevent off-
pathway aggregation, they may exert differential effects on 
non-ordered versus ordered aggregation. Thus we employed 
a fluorometric assay which depends on the altered fluorescent 
properties of ThT when bound to amyloid [19-21,23] that 
could distinguish these two types of aggregation. We studied 
amyloid formation by Aßx-42, since previous in vitro kinetic 
analyses have indicated that Aßi_42 formed amyloid at much 
higher rates than shorter Aßs [17]. 
3.1. Characterization of in vitro amyloid formation by Aßt_jg 
We characterized the ThT assay for Aßi_42 and found the 
data comparable in all respects to those of LeVine [23] who 
studied Aßi_40 with this assay. For this characterization we 
measured the initial rates of amyloid formation over a 6 h 
period and studied the effects of varying substrate and salt 
concentrations, temperature and pH (Table 1). ThT fluores-
cence increased linearly through 6 h and the initial rates were 
calculated by linear regression analysis (data not shown). 
There was a direct relationship between the initial concentra-
tion of Aßi_42 and the initial rate of amyloidogenesis (Table 
1). The rate of amyloid formation was directly related to the 
temperature (Table 1), suggesting that this reaction is hydro-
phobically driven. In agreement with previous studies [23,24], 
the rate of amyloid formation was minimal at low pH and 
maximal at pH 6.5-8.5 (Table 1). Electron micrographs of 
samples of the reactions at pH 6.5-9.5 exhibited prominent 
fibrils at pH 6.5, 7.4, 8.5 and 9.5 (data not shown). Interest-
ingly, the relative abundance and width (Table 1) of fibrils in 
a given EM field increased considerably above pH 7.4. These 
data suggest that fibril structure and ThT binding to fibrils are 
pH dependent. Na+ and K+ (50-100 mM) had only modest 
effects on amyloid formation, while 200 mM K+ inhibited the 
initial rate of amyloidogenesis. 
3.2. Effect of small heat shock proteins on amyloid formation 
The effects of adding various concentrations (0.5-3.0 |J.M) 
of human sHsp27 to a reaction containing 20 u\M Aßi_42 as a 
function of time is shown in Fig. 1A,B. After 24 h substoi-
chiometric amounts of sHsp27 exerted a significant 30% re-
duction in amyloid formation as assessed by the fluorescence 
assay at a molar ratio of 0.025. At higher molar ratios of 
sHsp/Aß1_42 there was a progressive increase in inhibition 
until at a ratio of 0.15, amyloid formation was inhibited by 
Table 1 
Effects of substrate concentration, temperature, pH and salt 
Aßj-42 (uM) 
5 
10 
20 
Parameter varied 
substrate concentration 
concentration on the initial rates of 
Initial ratea 
40.7 ±13.0* 
103.7 ±20.3* 
200.0 ±11.1 
Aßj. _42 amyloidogenesis 
Fibril width (nm)b 
20 
20 
temperature = 4°C 
temperature = 22°C 
temperature = 37°C 
pH = 3.4 
pH = 5.5 
pH = 6.5 
pH = 7.4 
pH = 8.5 
pH = 9.5 
14.8 ±7.4* 
251.9 ±18.5* 
400.0 ±7.4 
42.9 ±14.3* 
25.0 ±8.9* 
200.0 ±21.4 
162.5 ±41.1 
187.5 ±75.0 
100.0±16.1* 
not detected 
not detected 
6.1 ±0.4* 
10.5 ±0.4 
9.6 ±0.4 
13.8 ±0.5* 
20 Na+/K+ (0 mM) 
Na+ (50 mM) 
Na+ (100 mM) 
Na+ (200 mM) 
K+ (50 mM) 
K+ (100 mM) 
K+ (200 mM) 
200.0 ±5.7 
294.3 ±5.7 
256.6 ±22.6 
184.9 ±7.5 
230.2 ±25.7 
149.1 ±13.2 
124.5±15.1* 
a Average of linear regression slopes for 6 h kinetic data from three independent experiments expressed as arbitrary fluorescence units h~ 
bMeasured from electron micrographs. 
*Significantly different from control group (data in bold type) at the P < 0.05 level as described in Section 2. 
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Fig. 1. Kinetics of in vitro amyloid formation (A) and depolymeri-
zation (B) by Ap!_42 in the presence of increasing concentrations of 
human sHsp27. A: Kinetic analysis of ThT fluorescence intensity 
(arbitrary units) of 20 uM Aß!_42 in the absence (open circles) or 
presence of varying concentrations of sHsp27 (0.5 uM, closed 
squares; 1.5 uM, open triangles; 3.0 uM, closed triangles). B: De-
polymerization of pre-formed amyloid (from a reaction containing 
20 uM Aß!_42) in the absence (open circle) or presence of 0.5 uM 
(open squares) and 3.0 uM (closed triangles) of sHsp27. 
75% as assessed by the fluorescence assay (Fig. 1A). However, 
by 72 h there was no significant difference in the amount of 
amyloid in the absence or presence of 3.0 uM sHsp27, indi-
cating that the sHsp27 effect appeared to act on an early step 
in fibril formation without affecting fibril elongation (Fig. IB). 
When sHsp27 (0.5-3.0 uM) was added to pre-formed amyloid 
and incubated for varying periods of time there was a smaller 
decrease (6-36%) in the fluorescent signal (Fig. 1C). These 
data suggest that sHsp can destabilize amyloid fibrils to 
some extent; however, the dominant effect appears to be to 
inhibit the initiation of fibril formation. 
Fig. 2 shows the appearance of fibrils incubated in the pres-
ence (Fig. 2B,C) and absence (Fig. 2A) of 0.5 and 1.5 uM 
sHsp27 after 24 h. No significant differences in overall length 
or width of fibrils were apparent from the electron micro-
graphs. These data suggest that sHsps inhibit amyloid forma-
tion at an early step rather than exerting a dominant effect on 
fibril growth. 
The sHsps belong to a family of homologous proteins, 
which also includes the oc-crystallins. All members of this 
family are characterized by the presence of one or more a-
crystallin domains, which contain two predicted ß-sheet-rich 
motifs that are connected by a hydrophilic oc-helical region. 
We examined the influence of the a-crystallins and other un-
related proteins on amyloid formation. As shown in Table 2, 
an oc-crystallin preparation containing both A and B a-crys-
tallins lacked the ability to inhibit the initial rate of Aßi_42 
amyloid formation at the same concentration at which sHsp27 
or sHsp25 completely inhibited amyloidogenesis. Thus the 
sHsp effect appears to be a relatively specific phenomenon. 
Also, BSA and LDH had no effect on amyloid formation 
(Table 2). 
4. Discussion 
The interaction of ThT with amyloid appears to be specific 
to the extensive ß-pleated sheet structure present in the amy-
loid polymer [23], providing for the direct assessment of amy-
loid formation without the complication of signal from amor-
phous aggregation. Using this assay our data are in good 
agreement with those of LeVine [23] who utilized ThT fluo-
rescence to study Aßi_4o. The initial rates of amyloid forma-
tion were directly proportional to the concentration of Aßi_42 
and temperature (Table 1). Amyloid formation was maximal 
over a broad pH range (6.5-8.5) (Table 1). However, electron 
micrographs indicated dramatic increases in the amount of 
amyloid at pH 8.5 and 9.5 (data not shown) and significant 
differences in fibril width at pH 6.5 and 9.5 compared to pH 
7.4 (Table 1). Thus unique amyloid structures and/or ThT 
binding are dependent on pH. Salt (Na+ and K+) had only 
minor effects on the rate of amyloid formation (Table 1). 
These and earlier data [23] indicate that the ThT assay repre-
sents a highly specific amyloidogenesis assay for Aßs. 
Addition of substoichiometric levels of human sHsp27 or 
murine sHsp25 inhibited in vitro amyloid formation (Fig. 1, 
Table 2). Since the sHsp concentrations were based on mono-
mer molecular weights and sHsps exist as larger aggregates 
(ca. 200-800 kDa, 8-32 subunits), the sHsp effect occurs at a 
significantly lower molar ratio than its ability to refold citrate 
synthase and a-glucosidase in vitro [25]. Fibril formation is 
thought to involve a nucleation step, a metastable state, that 
involves the assembly of a 'seed' consisting of several subunits 
which serves as the 'template' for subsequent fibril growth 
[17,24]. Thus sHsps may interfere with the nucleation process, 
a conclusion supported by the findings that sHsps exert their 
effects in the early phase of the reaction (Fig. IB), exert lesser 
effects on amyloid depolymerization (Fig. 1C) and do not 
significantly affect fibril morphology (Fig. 2). 
Whether sHsps inhibit amyloidogenesis in vivo is unknown. 
The sHsps are normally present in the cytoplasm. Since 
Aßi_42 is formed by the processing of the integral membrane 
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Fig. 2. Electron micrographs of the reaction products of 20 uM Aßi_42 in the absence (A) or presence of 0.5 uM (B) and 3.0 uM (Q of 
sHsp27. The bars (A-C) represent 200 nm. 
protein precursor, APP, most probably within an endosomal-
lysosomal structure [26,27], it is unlikely that APP would in-
teract with chaperones that were restricted to the cytoplasm. 
Since the Hsp/chaperones represent a large family of highly 
conserved proteins with common functions that are responsi-
ble for protein complex assembly, disassembly and subcellular 
trafficking [18], the sHsp effect on amyloidogenesis may rep-
resent a redundant function, shared by other Hsps. Several 
families of Hsps are known and each family contains several 
cognate species. For example, the Hsp70 and Hsp60 families 
are ATPases, whereas sHsps are not [18]. The sHsp family 
includes the lens A and B oc-crystallins; however, these pro-
teins did not inhibit amyloid formation (Table 2). The sHsps 
are less well understood, but also function as molecular chap-
erones [25]. 
The concept that Hsp/chaperones may prevent amyloid for-
mation is attractive. First, amyloidogenesis may represent a 
unique form of off-pathway aggregation. Prevention of off-
pathway aggregation is an important mechanism by which 
Hsps promote correct protein folding. Second, chaperones 
have been implicated in the amyloid-associated prion ence-
phalopathies, where they may be involved in the protein con-
formational changes that accompany the normal prion PrP c 
to the disease-associated scrapie forms PrPSc [28]. Hsp70 has 
been co-localized with PrPSc in lysosomes where PrPSc is pro-
posed to be generated [28] and a 73 kDa Hsp70 family mem-
ber enhances in vitro protein degradation of two different 
lysosomal systems [29]. Also, Hspl04 plays a central role in 
modulating the prion-like state associated with the non-Men-
delian inherited [PSI] phenotype in yeast [30,31]. Finally, 
most amyloidoses are age-related diseases that are correlated 
with an aging-associated decrease in the Hsp/chaperone stress 
response observed in several lymphocytes [32,33], heart [34], 
and hepatocytes [35]. The post-translational modification of 
a-crystallin during aging is correlated with the loss of its 
chaperone functions [36]. Finally, Hsp70 mRNA levels in 
mononuclear blood cells from Alzheimer patients were signifi-
cantly lower than those from patients with vascular dementia 
and non-demented controls [37]. 
It is important to stress that several other proteins, includ-
ing apolipoproteins E and J (apoE and apoJ) and transthyr-
etin, have been implicated in modulating amyloid formation 
or function. Distinct alíeles of apoE have been reported to 
inhibit (apoE3) or promote (apoE4) amyloid formation, pos-
sibly by influencing the rate of APP secretion [38]. ApoJ, a 
widely distributed protein, inhibits toxicity of Aßi_4o in vitro 
Table 2 
Effect of sHsp27 and other proteins on initial rates of Aßi_42 amyloidogenesis 
Aßi_42 concentration Protein added (uM) Initial rate8 
20 
human sHsp27 (0.75) 
human sHsp27 (1.54) 
human sHsp27 (3.08) 
human sHsp27 (6.18) 
200.0 ±6.9 
103.4± 1.5* 
41.3± 12.1* 
27.5 ±11.5* 
-41.3 ±20.7* 
20 
20 
none 
mouse sHsp25 (6.18) 
none 
a-crystallin (6.18) 
LDH (6.18) 
BSA(6.18) 
156.5 ±6.5 
-26.1 ±4.3* 
210.3 ±5.7 
194.3 ±11.4 
200.0 ±8.6 
162.5 ±14.3 
* Average of regression slopes for 6 h kinetic data from three independent experiments expressed as arbitrary fluoescence units h 
*Significantly different from control group (data in bold type) at the P < 0.05 level as described in Section 2. 
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[39]. Transthyretin, a major component of cerebrospinal fluid, 
has also been shown to prevent amyloid formation in vitro 
[40]. Whether any of these proteins or the Hsp/chaperone 
family exert physiologic roles modulat ing Aß amyloidogenesis 
in the central nervous system will require further investiga-
tion. 
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